{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T21:11:50Z","timestamp":1774991510602,"version":"3.50.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GRK2762\/1"],"award-info":[{"award-number":["GRK2762\/1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["RE 2857\/2-1"],"award-info":[{"award-number":["RE 2857\/2-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GRK2769\/1"],"award-info":[{"award-number":["GRK2769\/1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Diffuse midline glioma H3K27M-altered (DMG) remains a fatal pediatric brain cancer driven by a global loss of histone H3K27 trimethylation. Radiotherapy comprises the most important treatment modality and significantly improves overall survival. Novel therapeutic strategies for DMG patients without or with radiotherapy are urgently needed. Here, we aimed to gain insights into potential radiation response modulators. To identify modulators of radiation response, we performed a high-throughput drug screening (HTS) in seven representative DMG cell lines using conventional chemotherapeutic drugs and phase I-IV drugs (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009687), followed by irradiation with 0 or 2\u2009\u00d7\u20094 Gray (Gy). The ataxia\u2013telangiectasia and Rad3-related (ATR) inhibitor berzosertib emerged as a potent radiosensitizer. Its effects were validated in three DMG cell lines using short-term proliferation assays, long-term limiting dilution assays (LDA), 3D spheroid cultures, and the chorioallantoic membrane (CAM) assay\n                    <jats:italic>in ovo<\/jats:italic>\n                    . Across all three tested DMG cell line models, berzosertib enhanced the antineoplastic effects of clinically relevant radiation doses, significantly reducing proliferation and clonogenic survival, delaying spheroid growth, and suppressing tumor formation\n                    <jats:italic>in ovo<\/jats:italic>\n                    . These findings provide strong preclinical evidence that ATR inhibition increases the sensitivity of DMG cells to radiotherapy. They highlight a novel therapeutic vulnerability and support further exploration of ATR inhibitors in rational combination strategies to improve radiotherapy efficacy for this deadly disease.\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-08567-7","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T23:05:42Z","timestamp":1774047942000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Berzosertib enhances the sensitivity of pediatric diffuse midline glioma H3K27-altered cells to radiotherapy"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7935-5991","authenticated-orcid":false,"given":"Nikita","family":"Gorainow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Sander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Picard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marvin Christopher","family":"Fr\u00f6lich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Eul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Etemadi Afshar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Asche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3547-237X","authenticated-orcid":false,"given":"Michelle","family":"Monje","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Raabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmin","family":"Bartl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6121-4737","authenticated-orcid":false,"given":"Arndt","family":"Borkhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Reifenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1273-0644","authenticated-orcid":false,"given":"Nicole","family":"D\u00fcnker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9651-031X","authenticated-orcid":false,"given":"Maike","family":"Busch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Pauck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3442-8043","authenticated-orcid":false,"given":"Nan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4878-8741","authenticated-orcid":false,"given":"Johann","family":"Matschke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Remke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1058-2107","authenticated-orcid":false,"given":"Verena","family":"Jendrossek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"key":"8567_CR1","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3389\/fonc.2015.00237","volume":"5","author":"MI Vanan","year":"2015","unstructured":"Vanan MI, Eisenstat DD. DIPG in Children\u2014What Can We Learn from the Past? Front Oncol. 2015;5:237.","journal-title":"Front Oncol"},{"key":"8567_CR2","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1093\/neuonc\/noaf061","volume":"27","author":"MK Mateos","year":"2025","unstructured":"Mateos MK, Ajuyah P, Fuentes-Bolanos N, El-Kamand S, Barahona P, Altekoester AK, et al. Germline analysis of an international cohort of pediatric diffuse midline glioma patients. Neuro Oncol. 2025;27:1849\u201363.","journal-title":"Neuro Oncol"},{"key":"8567_CR3","doi-asserted-by":"publisher","first-page":"301","DOI":"10.2176\/nmc.ra.2017-0010","volume":"57","author":"T Komori","year":"2017","unstructured":"Komori T. The 2016 WHO Classification of Tumours of the Central Nervous System: the major points of revision. Neurol Med Chir. 2017;57:301\u201311.","journal-title":"Neurol Med Chir"},{"key":"8567_CR4","doi-asserted-by":"crossref","unstructured":"Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016 803\u201320.","DOI":"10.1007\/s00401-016-1545-1"},{"key":"8567_CR5","doi-asserted-by":"publisher","first-page":"1082062","DOI":"10.3389\/fonc.2022.1082062","volume":"12","author":"SG Vallero","year":"2022","unstructured":"Vallero SG, Bertero L, Morana G, Sciortino P, Bertin D, Mussano A, et al. Pediatric diffuse midline glioma H3K27- altered: a complex clinical and biological landscape behind a neatly defined tumor type. Front Oncol. 2022;12:1082062.","journal-title":"Front Oncol"},{"key":"8567_CR6","first-page":"104","volume":"12","author":"K Wi\u015bniewski","year":"2023","unstructured":"Wi\u015bniewski K, Ghaly A, Drummond K, Fahlstr\u04e7m A. H3\u2009K27M-altered diffuse midline gliomas: a review. Indian. J Neurosurg. 2023;12:104\u201315.","journal-title":"J Neurosurg"},{"key":"8567_CR7","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/pr.2013.194","volume":"75","author":"KM Schroeder","year":"2014","unstructured":"Schroeder KM, Hoeman CM, Becher OJ. Children are not just little adults: recent advances in understanding of diffuse intrinsic pontine glioma biology. Pediatr Res. 2014;75:205\u20139.","journal-title":"Pediatr Res"},{"key":"8567_CR8","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.ccell.2023.03.007","volume":"41","author":"CX Sun","year":"2023","unstructured":"Sun CX, Daniel P, Bradshaw G, Shi H, Loi M, Chew N, et al. Generation and multi-dimensional profiling of a childhood cancer cell line atlas defines new therapeutic opportunities. Cancer Cell. 2023;41:e7.","journal-title":"Cancer Cell"},{"key":"8567_CR9","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00401-023-02609-6","volume":"146","author":"EA Williams","year":"2023","unstructured":"Williams EA, Brastianos PK, Wakimoto H, Zolal A, Filbin MG, Cahill DP, et al. A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4. Acta Neuropathol. 2023;146:515\u201325.","journal-title":"Acta Neuropathol"},{"key":"8567_CR10","doi-asserted-by":"crossref","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021 1231\u201351.","DOI":"10.1093\/neuonc\/noab106"},{"key":"8567_CR11","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1200\/JCO.23.01134","volume":"42","author":"I Arrillaga-Romany","year":"2024","unstructured":"Arrillaga-Romany I, Gardner SL, Odia Y, Aguilera D, Allen JE, Batchelor T, et al. ONC201 (Dordaviprone) in recurrent H3 K27M-mutant diffuse midline glioma. J Clin Oncol. 2024;42:1542\u201352.","journal-title":"J Clin Oncol"},{"key":"8567_CR12","doi-asserted-by":"publisher","first-page":"175883592211136","DOI":"10.1177\/17588359221113693","volume":"14","author":"G Del Baldo","year":"2022","unstructured":"Del Baldo G, Carai A, Abbas R, Cacchione A, Vinci M, Di Ruscio V, et al. Targeted therapy for pediatric diffuse intrinsic pontine glioma: a single-center experience. Ther Adv Med Oncol. 2022;14:17588359221113693.","journal-title":"Ther Adv Med Oncol"},{"key":"8567_CR13","first-page":"vdac143","volume":"4","author":"SL Gardner","year":"2022","unstructured":"Gardner SL, Tarapore RS, Allen J, McGovern SL, Zaky W, Odia Y, et al. Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy. Neurooncol Adv. 2022;4:vdac143.","journal-title":"Neurooncol Adv"},{"key":"8567_CR14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/BF00263825","volume":"7","author":"IA Langmoen","year":"1991","unstructured":"Langmoen IA, Lundar T, Storm-Mathisen I, Lie SO, Hovind KH. Management of pediatric pontine gliomas. Child's Nerv Syst. 1991;7:13\u20135.","journal-title":"Child's Nerv Syst"},{"key":"8567_CR15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.radonc.2014.01.013","volume":"111","author":"MS Zaghloul","year":"2014","unstructured":"Zaghloul MS, Eldebawy E, Ahmed S, Mousa AG, Amin A, Refaat A, et al. Hypofractionated conformal radiotherapy for pediatric diffuse intrinsic pontine glioma (DIPG): a randomized controlled trial. Radiother Oncol. 2014;111:35\u201340.","journal-title":"Radiother Oncol"},{"key":"8567_CR16","doi-asserted-by":"publisher","first-page":"5280.","DOI":"10.3390\/cancers13215280","volume":"13","author":"DP Argersinger","year":"2021","unstructured":"Argersinger DP, Rivas SR, Shah AH, Jackson S, Heiss JD. New developments in the pathogenesis, therapeutic targeting, and treatment of H3K27M-mutant diffuse midline glioma. Cancers. 2021;13:5280.","journal-title":"Cancers"},{"key":"8567_CR17","doi-asserted-by":"publisher","first-page":"88","DOI":"10.2174\/1570159X14666160509123229","volume":"15","author":"TB Johung","year":"2017","unstructured":"Johung TB, Monje M. Diffuse intrinsic pontine glioma: new pathophysiological insights and emerging therapeutic targets. Curr Neuropharmacol. 2017;15:88\u201397.","journal-title":"Curr Neuropharmacol"},{"key":"8567_CR18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s11060-019-03140-z","volume":"143","author":"G Fleischhack","year":"2019","unstructured":"Fleischhack G, Massimino M, Warmuth-Metz M, Khuhlaeva E, Janssen G, Graf N, et al. Nimotuzumab and radiotherapy for treatment of newly diagnosed diffuse intrinsic pontine glioma (DIPG): a phase III clinical study. J Neuro Oncol. 2019;143:107\u201313.","journal-title":"J Neuro Oncol"},{"key":"8567_CR19","doi-asserted-by":"publisher","first-page":"e26832","DOI":"10.1002\/pbc.26832","volume":"65","author":"LB Kilburn","year":"2018","unstructured":"Kilburn LB, Kocak M, Baxter P, Poussaint TY, Paulino AC, McIntyre C, et al. A pediatric brain tumor consortium phase II trial of capecitabine rapidly disintegrating tablets with concomitant radiation therapy in children with newly diagnosed diffuse intrinsic pontine gliomas. Pediatr Blood Cancer. 2018;65:e26832.","journal-title":"Pediatr Blood Cancer"},{"key":"8567_CR20","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11060-017-2575-9","volume":"135","author":"SE Veldhuijzen van Zanten","year":"2017","unstructured":"Veldhuijzen van Zanten SE, El-Khouly FE, Jansen MH, Bakker DP, Sanchez Aliaga E, Haasbeek CJ, et al. A phase I\/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma. J Neuro Oncol. 2017;135:307\u201315.","journal-title":"J Neuro Oncol"},{"key":"8567_CR21","first-page":"vdac073","volume":"4","author":"S Mueller","year":"2022","unstructured":"Mueller S, Cooney T, Yang X, Pal S, Ermoian R, Gajjar A, et al. Wee1 kinase inhibitor adavosertib with radiation in newly diagnosed diffuse intrinsic pontine glioma: a Children\u2019s Oncology Group phase I consortium study. Neurooncol Adv. 2022;4:vdac073.","journal-title":"Neurooncol Adv"},{"key":"8567_CR22","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/nm0715-827a","volume":"21","author":"CS Grasso","year":"2015","unstructured":"Grasso CS, Tang Y, Truffaux N, Berlow NE, Liu L, Debily MA, et al. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat Med. 2015;21:827.","journal-title":"Nat Med"},{"key":"8567_CR23","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s11060-023-04508-y","volume":"165","author":"N Qin","year":"2023","unstructured":"Qin N, Paisana E, Picard D, Leprivier G, Langini M, Cust\u00f3dia C, et al. The long non-coding RNA OTX2-AS1 promotes tumor growth and predicts response to BCL-2 inhibition in medulloblastoma. J Neurooncol. 2023;165:329\u201342.","journal-title":"J Neurooncol"},{"key":"8567_CR24","doi-asserted-by":"publisher","first-page":"3086.","DOI":"10.3390\/cancers13123086","volume":"13","author":"M Fiorentzis","year":"2021","unstructured":"Fiorentzis M, Sokolenko EA, Bechrakis NE, Ting S, Schmid KW, Sak A, et al. Electrochemotherapy with bleomycin enhances radiosensitivity of uveal melanomas: first in vitro results in 3D cultures of primary uveal melanoma cell lines. Cancers. 2021;13:3086.","journal-title":"Cancers."},{"key":"8567_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41420-024-01805-x","volume":"10","author":"K Xiang","year":"2024","unstructured":"Xiang K, Kunin M, Larafa S, Busch M, Dunker N, Jendrossek V, et al. alpha-Ketoglutarate supplementation and NAD+ modulation enhance metabolic rewiring and radiosensitization in SLC25A1- inhibited cancer cells. Cell Death Discov. 2024;10:27.","journal-title":"Cell Death Discov"},{"key":"8567_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05098-9","volume":"13","author":"K Xiang","year":"2022","unstructured":"Xiang K, Kalthoff C, Munch C, Jendrossek V, Matschke J. Accumulation of oncometabolite D-2-Hydroxyglutarate by SLC25A1 inhibition: a metabolic strategy for induction of HR-ness and radiosensitivity. Cell Death Dis. 2022;13:641.","journal-title":"Cell Death Dis"},{"key":"8567_CR27","doi-asserted-by":"publisher","first-page":"W739","DOI":"10.1093\/nar\/gkac382","volume":"50","author":"A Ianevski","year":"2022","unstructured":"Ianevski A, Giri AK, Aittokallio T. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res. 2022;50:W739\u2013W43.","journal-title":"Nucleic Acids Res"},{"key":"8567_CR28","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jim.2009.06.008","volume":"347","author":"Y Hu","year":"2009","unstructured":"Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods. 2009;347:70\u20138.","journal-title":"J Immunol Methods"},{"key":"8567_CR29","doi-asserted-by":"publisher","first-page":"107485","DOI":"10.1016\/j.celrep.2020.03.049","volume":"31","author":"NA Dahl","year":"2020","unstructured":"Dahl NA, Danis E, Balakrishnan I, Wang D, Pierce A, Walker FM, et al. Super elongation complex as a targetable dependency in diffuse midline glioma. Cell Rep. 2020;31:107485.","journal-title":"Cell Rep"},{"key":"8567_CR30","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s11060-020-03643-0","volume":"149","author":"JH McAbee","year":"2020","unstructured":"McAbee JH, Degorre-Kerbaul C, Valdez K, Wendler A, Shankavaram UT, Watts C, et al. Detection of glioblastoma intratumor heterogeneity in radiosensitivity using patient-derived neurosphere cultures. J Neurooncol. 2020;149:383\u201390.","journal-title":"J Neurooncol"},{"key":"8567_CR31","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1158\/1078-0432.CCR-19-3538","volume":"26","author":"MH Meel","year":"2020","unstructured":"Meel MH, de Gooijer MC, Metselaar DS, Sewing ACP, Zwaan K, Waranecki P, et al. Combined therapy of AXL and HDAC inhibition reverses mesenchymal transition in diffuse intrinsic pontine glioma. Clin Cancer Res. 2020;26:3319\u201332.","journal-title":"Clin Cancer Res"},{"key":"8567_CR32","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jconrel.2023.03.058","volume":"357","author":"E Hart","year":"2023","unstructured":"Hart E, Bianco J, Bruin MAC, Derieppe M, Besse HC, Berkhout K, et al. Radiosensitisation by olaparib through focused ultrasound delivery in a diffuse midline glioma model. J Control Release. 2023;357:287\u201398.","journal-title":"J Control Release"},{"key":"8567_CR33","first-page":"100920","volume":"51","author":"C Beckers","year":"2025","unstructured":"Beckers C, Vasilikos L, Moor L, Pruschy M. Live-cell imaging and analysis of 3D spheroids in hypoxia- and radiotherapy-related research. Clin Transl. Radiat Oncol. 2025;51:100920.","journal-title":"Clin Transl. Radiat Oncol"},{"key":"8567_CR34","doi-asserted-by":"publisher","first-page":"e0263822","DOI":"10.1371\/journal.pone.0263822","volume":"17","author":"EA Power","year":"2022","unstructured":"Power EA, Fernandez-Torres J, Zhang L, Yaun R, Lucien F, Daniels DJ. Chorioallantoic membrane (CAM) assay to study treatment effects in diffuse intrinsic pontine glioma. PLoS ONE. 2022;17:e0263822.","journal-title":"PLoS ONE"},{"key":"8567_CR35","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/ng.2938","volume":"46","author":"G Wu","year":"2014","unstructured":"Wu G, Diaz AK, Paugh BS, Rankin SL, Ju B, Li Y, et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet. 2014;46:444\u201350.","journal-title":"Nat Genet"},{"key":"8567_CR36","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1124\/jpet.121.000845","volume":"379","author":"S Talele","year":"2021","unstructured":"Talele S, Zhang W, Burgenske DM, Kim M, Mohammad AS, Dragojevic S, et al. Brain distribution of berzosertib: an ataxia telangiectasia and rad3-related protein inhibitor for the treatment of glioblastoma. J Pharmacol Exp Ther. 2021;379:343\u201357.","journal-title":"J Pharmacol Exp Ther"},{"key":"8567_CR37","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.ccell.2021.02.014","volume":"39","author":"A Thomas","year":"2021","unstructured":"Thomas A, Takahashi N, Rajapakse VN, Zhang X, Sun Y, Ceribelli M, et al. Therapeutic targeting of ATR yields durable regressions in small-cell lung cancers with high replication stress. Cancer Cell. 2021;39:566\u201379.e7.","journal-title":"Cancer Cell"},{"key":"8567_CR38","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1007\/s10637-023-01408-w","volume":"41","author":"J Schnoell","year":"2023","unstructured":"Schnoell J, Sparr C, Al-Gboore S, Haas M, Brkic FF, Kadletz-Wanke L, et al. The ATR inhibitor berzosertib acts as a radio- and chemosensitizer in head and neck squamous cell carcinoma cell lines. Invest N Drugs. 2023;41:842\u201350.","journal-title":"Invest N Drugs"},{"key":"8567_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2012.181","volume":"3","author":"E Fokas","year":"2012","unstructured":"Fokas E, Prevo R, Pollard JR, Reaper PM, Charlton PA, Cornelissen B, et al. Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death Dis. 2012;3:e441.","journal-title":"Cell Death Dis"},{"key":"8567_CR40","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3390\/cancers10080275","volume":"10","author":"FK Middleton","year":"2018","unstructured":"Middleton FK, Pollard JR, Curtin NJ. The impact of p53 dysfunction in ATR inhibitor cytotoxicity and chemo- and radiosensitisation. Cancers. 2018;10:275.","journal-title":"Cancers."},{"key":"8567_CR41","doi-asserted-by":"publisher","first-page":"5643","DOI":"10.1158\/1078-0432.CCR-24-0154","volume":"30","author":"V Ng","year":"2024","unstructured":"Ng V, Sinha S, Novaj A, Ma J, McDermott N, Pei X, et al. Genotype-directed synthetic cytotoxicity of ATR inhibition with radiotherapy. Clin Cancer Res. 2024;30:5643\u201356.","journal-title":"Clin Cancer Res"},{"key":"8567_CR42","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1016\/j.dnarep.2008.08.014","volume":"7","author":"CJ Lord","year":"2008","unstructured":"Lord CJ, McDonald S, Swift S, Turner NC, Ashworth A. A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. DNA Repair. 2008;7:2010\u20139.","journal-title":"DNA Repair"},{"key":"8567_CR43","doi-asserted-by":"publisher","first-page":"4780","DOI":"10.1158\/1078-0432.CCR-15-0479","volume":"21","author":"LM Karnitz","year":"2015","unstructured":"Karnitz LM, Zou L. Molecular pathways: targeting ATR in cancer therapy. Clin Cancer Res. 2015;21:4780\u20135.","journal-title":"Clin Cancer Res"},{"key":"8567_CR44","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nrm2450","volume":"9","author":"KA Cimprich","year":"2008","unstructured":"Cimprich KA, Cortez D. ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol. 2008;9:616\u201327.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8567_CR45","doi-asserted-by":"publisher","first-page":"e179599","DOI":"10.1172\/jci.insight.179599","volume":"9","author":"SJ Bright","year":"2024","unstructured":"Bright SJ, Manandhar M, Flint DB, Kolachina R, Ben Kacem M, Martinus DK, et al. ATR inhibition radiosensitizes cells through augmented DNA damage and G2 cell cycle arrest abrogation. JCI Insight. 2024;9:e179599.","journal-title":"JCI Insight"},{"key":"8567_CR46","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1158\/1535-7163.MCT-18-0470","volume":"17","author":"X Tu","year":"2018","unstructured":"Tu X, Kahila MM, Zhou Q, Yu J, Kalari KR, Wang L, et al. ATR inhibition is a promising radiosensitizing strategy for triple-negative breast cancer. Mol Cancer Ther. 2018;17:2462\u201372.","journal-title":"Mol Cancer Ther"},{"key":"8567_CR47","doi-asserted-by":"publisher","first-page":"10546","DOI":"10.18632\/oncotarget.2508","volume":"5","author":"JP Mak","year":"2014","unstructured":"Mak JP, Man WY, Ma HT, Poon RY. Pharmacological targeting of the ATR-CHK1-WEE1 axis involves balancing cell growth stimulation and apoptosis. Oncotarget. 2014;5:10546\u201357.","journal-title":"Oncotarget."},{"key":"8567_CR48","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1038\/nsmb.2189","volume":"18","author":"M Murga","year":"2011","unstructured":"Murga M, Campaner S, L\u00f3pez-Contreras AJ, Toledo LI, Soria R, Montana MF, et al. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat Struct Mol Biol. 2011;18:1331\u20135.","journal-title":"Nat Struct Mol Biol"},{"key":"8567_CR49","doi-asserted-by":"publisher","first-page":"9693","DOI":"10.1158\/0008-5472.CAN-10-2286","volume":"70","author":"O Gilad","year":"2010","unstructured":"Gilad O, Nabet BY, Ragland RL, Schoppy DW, Smith KD, Durham AC, et al. Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner. Cancer Res. 2010;70:9693\u2013702.","journal-title":"Cancer Res"},{"key":"8567_CR50","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/s41416-020-1016-2","volume":"123","author":"CR Dunlop","year":"2020","unstructured":"Dunlop CR, Wallez Y, Johnson TI, Bernaldo de Quiros Fernandez S, Durant ST, Cadogan EB, et al. Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models. Br J Cancer. 2020;123:1424\u201336.","journal-title":"Br J Cancer"},{"key":"8567_CR51","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1158\/0008-5472.CAN-19-3126","volume":"80","author":"S Rafiei","year":"2020","unstructured":"Rafiei S, Fitzpatrick K, Liu D, Cai MY, Elmarakeby HA, Park J, et al. ATM loss confers greater sensitivity to ATR inhibition than PARP inhibition in prostate cancer. Cancer Res. 2020;80:2094\u2013100.","journal-title":"Cancer Res"},{"key":"8567_CR52","doi-asserted-by":"publisher","first-page":"156980","DOI":"10.1016\/j.cyto.2025.156980","volume":"193","author":"N van Campen","year":"2025","unstructured":"van Campen N, Mekers VE, Looman MW, van den Bogaard L, Kers-Rebel ED, Peeters WJM, et al. ATM and ATR inhibition increases radiosensitivity and cGAS-STING activation in prostate cancer. Cytokine. 2025;193:156980.","journal-title":"Cytokine."},{"key":"8567_CR53","doi-asserted-by":"publisher","first-page":"6788","DOI":"10.1158\/1078-0432.CCR-19-0126","volume":"25","author":"C Werbrouck","year":"2019","unstructured":"Werbrouck C, Evangelista CCS, Lobon-Iglesias MJ, Barret E, Le Teuff G, Merlevede J, et al. TP53 pathway alterations drive radioresistance in diffuse intrinsic pontine gliomas (DIPG). Clin Cancer Res. 2019;25:6788\u2013800.","journal-title":"Clin Cancer Res"},{"key":"8567_CR54","doi-asserted-by":"publisher","first-page":"e142158","DOI":"10.1172\/JCI142158","volume":"131","author":"K Deland","year":"2021","unstructured":"Deland K, Starr BF, Mercer JS, Byemerwa J, Crabtree DM, Williams NT, et al. Tumor genotype dictates radiosensitization after Atm deletion in primary brainstem glioma models. J Clin Investig. 2021;131:e142158.","journal-title":"J Clin Investig"},{"key":"8567_CR55","doi-asserted-by":"publisher","first-page":"e179395","DOI":"10.1172\/JCI179395","volume":"135","author":"A Mangoli","year":"2025","unstructured":"Mangoli A, Valentine V, Maingi SM, Wu SR, Liu HQ, Aksu M, et al. Disruption of ataxia telangiectasia-mutated kinase enhances radiation therapy efficacy in spatially directed diffuse midline glioma models. J Clin Investig. 2025;135:e179395.","journal-title":"J Clin Investig"},{"key":"8567_CR56","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1093\/neuonc\/noaf216","volume":"28","author":"Z Jiang","year":"2025","unstructured":"Jiang Z, Xie L, Zhou H, Geng Y, Xiao X, Li T, et al. Transcriptomics-guided high-throughput drug screening identifies potent therapies for P53 pathway-altered DIPG\/DMG. Neuro Oncol. 2025;28:251\u201367.","journal-title":"Neuro Oncol"},{"key":"8567_CR57","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1158\/1535-7163.MCT-12-0735","volume":"12","author":"V Caretti","year":"2013","unstructured":"Caretti V, Hiddingh L, Lagerweij T, Schellen P, Koken PW, Hulleman E, et al. WEE1 kinase inhibition enhances the radiation response of diffuse intrinsic pontine gliomas. Mol Cancer Ther. 2013;12:141\u201350.","journal-title":"Mol Cancer Ther"},{"key":"8567_CR58","doi-asserted-by":"publisher","first-page":"4506","DOI":"10.3390\/cancers14184506","volume":"14","author":"CE Stewart","year":"2022","unstructured":"Stewart CE, Guerra-Garcia ME, Luo L, Williams NT, Ma Y, Regal JA, et al. The effect of Atm loss on radiosensitivity of a primary mouse model of pten-deleted brainstem glioma. Cancers. 2022;14:4506.","journal-title":"Cancers."},{"key":"8567_CR59","doi-asserted-by":"publisher","first-page":"8717","DOI":"10.3390\/ijms24108717","volume":"24","author":"S Kumar","year":"2023","unstructured":"Kumar S, Gahramanov V, Patel S, Yaglom J, Kaczmarczyk L, Alexandrov IA, et al. Evolution of resistance to irinotecan in cancer cells involves the generation of topoisomerase-guided mutations in the non-coding genome that reduce the chances of DNA breaks. Int J Mol Sci. 2023;24:8717.","journal-title":"Int J Mol Sci"},{"key":"8567_CR60","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1200\/JCO.19.00730","volume":"37","author":"KC Cuneo","year":"2019","unstructured":"Cuneo KC, Morgan MA, Sahai V, Schipper MJ, Parsels LA, Parsels JD, et al. Dose escalation trial of the Wee1 inhibitor adavosertib (AZD1775) in combination with gemcitabine and radiation for patients with locally advanced pancreatic cancer. J Clin Oncol. 2019;37:2643\u201350.","journal-title":"J Clin Oncol"},{"key":"8567_CR61","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1001\/jamaoncol.2022.5074","volume":"8","author":"P Loap","year":"2022","unstructured":"Loap P, Loirat D, Berger F, Rodrigues M, Bazire L, Pierga JY, et al. Concurrent olaparib and radiotherapy in patients with triple-negative breast cancer: the phase 1 olaparib and radiation therapy for triple-negative breast cancer trial. JAMA Oncol. 2022;8:1802\u20138.","journal-title":"JAMA Oncol"},{"key":"8567_CR62","doi-asserted-by":"publisher","first-page":"e2300635","DOI":"10.1200\/PO.23.00635","volume":"8","author":"PA Konstantinopoulos","year":"2024","unstructured":"Konstantinopoulos PA, Cheng SC, Lee EK, da Costa A, Gulhan D, Wahner Hendrickson AE, et al. Randomized phase II study of gemcitabine with or without atr inhibitor berzosertib in platinum-resistant ovarian cancer: final overall survival and biomarker analyses. JCO precis. Oncol. 2024;8:e2300635.","journal-title":"JCO precis. Oncol"},{"key":"8567_CR63","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/s41416-023-02542-1","volume":"130","author":"SR Javed","year":"2024","unstructured":"Javed SR, Lord S, El Badri S, Harman R, Holmes J, Kamzi F, et al. CHARIOT: a phase I study of berzosertib with chemoradiotherapy in oesophageal and other solid cancers using time to event continual reassessment method. Br J Cancer. 2024;130:467\u201375.","journal-title":"Br J Cancer"},{"key":"8567_CR64","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41416-021-01405-x","volume":"125","author":"MR Middleton","year":"2021","unstructured":"Middleton MR, Dean E, Evans TRJ, Shapiro GI, Pollard J, Hendriks BS, et al. Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine +\/- cisplatin in patients with advanced solid tumours. Br J Cancer. 2021;125:510\u20139.","journal-title":"Br J Cancer"},{"key":"8567_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18632\/oncotarget.28551","volume":"15","author":"M Lozinski","year":"2024","unstructured":"Lozinski M, Bowden NA, Graves MC, Fay M, Day BW, Stringer BW, et al. ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines. Oncotarget. 2024;15:1\u201318.","journal-title":"Oncotarget."},{"key":"8567_CR66","doi-asserted-by":"publisher","first-page":"12735","DOI":"10.1021\/acs.jmedchem.4c00734","volume":"67","author":"Z Liu","year":"2024","unstructured":"Liu Z, Jiang K, Liu Y, Li J, Huang S, Li P, et al. Discovery of preclinical candidate AD1058 as a highly potent, selective, and brain-penetrant atr inhibitor for the treatment of advanced malignancies. J Med Chem. 2024;67:12735\u201359.","journal-title":"J Med Chem"},{"key":"8567_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-018-1020-3","volume":"13","author":"G Frosina","year":"2018","unstructured":"Frosina G, Profumo A, Marubbi D, Marcello D, Ravetti JL, Daga A. ATR kinase inhibitors NVP-BEZ235 and AZD6738 effectively penetrate the brain after systemic administration. Radiat Oncol. 2018;13:76.","journal-title":"Radiat Oncol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08567-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08567-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08567-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T20:02:21Z","timestamp":1774987341000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08567-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8567"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08567-7","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"assertion":[{"value":"1 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study did not involve human participants or vertebrate animals requiring ethical approval. All experiments were conducted using established human cell lines and fertilized chicken eggs (CAM assay) prior to hatching; therefore, ethical approval was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"331"}}